Source: Business Wire
WOBURN, Mass.–(BUSINESS WIRE)–Javelin Biotech today announces a 3-year collaboration with Pfizer to design and build a platform to evaluate ADME properties of small molecule drugs.
FDA accepts Pfizer application for expanded use of Xalkori (NYSE:PFE)
Source: Seeking Alpha
The FDA accepts for review Pfizer’s (NYSE:PFE) supplemental marketing application seeking approval to use Xalkori (crizotinib) to treat pediatric patients
Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease
Source: Business Wire
PARIS & NEW YORK–(BUSINESS WIRE)–Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (NYSE: PFE) announced today that they have entered into a manufacturing agreement, under which Pfizer will provide clinical supply for a Phase 1/2 clinical trial evaluating Vivet’s proprietary, investigational gene therapy, VTX-801, for the potential treatment of Wilson diseas
COVID-19 vaccine credibility collapsing – MacroBusiness
Source: Macro Business
It’s not the fruitloop anti-vaxxers fault, either. It’s governments. Via Bloomberg: The Covid-19 vaccine trial designed by Pfizer Inc. and its German partner BioNTech SE may allow them to find whether their shot works before their fastest-moving rivals. The companies plan a first look after a mere 32 coronavirus infections have accumulated in their massive
Pfizer Invites Public to View and Listen to Webcast of October 27 Conference Call with Analysts
Source: Business Wire
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 27, 2020. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2020 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Info
Pfizer could secure first approval for COVID-19 vaccine, says Trump
Source: Business Today
Asked which drugmaker could be approved, Trump told Fox News in an interview:
Trump suggests Pfizer could win U.S. COVID-19 vaccine approval, JNJ to come later
Source: Reuters
U.S. President Donald Trump on Monday suggested Pfizer Inc could secure the first U.S. approval of a COVID-19 vaccine in coming weeks, saying a contender by Johnson & Johnson could come later.
Pfizer Reveals Efficacy Criteria For Key Covid-19 Vaccine Trials
Source: Smarter Analyst
Pfizer (PFE), and its partner BioNTech, have taken the rare step of publishing the clinical protocol for their late-stage Covid-19 vaccine trials. The vaccine … The post Pfizer Reveals Efficacy Criteria For Key Covid-19 Vaccine Trials appeared first on Smarter Analyst .
Global Anticoagulants (Xarelto, Eliquis, Pradaxa and Savaysa) Market to 2024 Featuring Key Players – Bayer, BMS/Pfizer, Boehringer Ingelheim and Daiichi Sankyo
Source: Benzinga
DUBLIN , Sept. 18, 2020 /PRNewswire/ — The “Global Anticoagulants Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024 Edition)” report has been added to ResearchAndMarkets.com’s offering. Bayer Group, BMS/Pfizer, Boehringer Ingelheim and Daiichi Sankyo are some of the key players operating in the global anticoagulants market, who’s Company Profiles has been done in the report. This segment summarizes business overview, financial overview and the business strategies of the companies. The report also provides an analysis of injectable and oral anticoagulants available in the market. Details of Lovenox, Arixtra, Xarelto, Eliquis, Pradaxa and Savaysa has been provided in the report in terms of their global sales. A brief analysis of the US anticoagulants market has also been provided in terms of value and sales of top four oral anticoagulant drugs in the region. The most commonly prescribed anticoagulant is Warfarin. Newer types of anticoagulants are also available and are becoming increasingly common.
Pfizer vaccine trial bets on early win against coronavirus
Source: Deccan Herald
Pfizer Inc is betting that its coronavirus vaccine candidate will show clear evidence of effectiveness early in its clinical trial, according to the company and internal documents reviewed by Reuters that describe how the trial is being run. In recent weeks, Pfizer has said it should know by the end of October whether the vaccine, developed together with Germany’s BioNTech SE,
